These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2874888)

  • 1. Analysis of the transforming potential of the human homolog of mos.
    Blair DG; Oskarsson MK; Seth A; Dunn KJ; Dean M; Zweig M; Tainsky MA; Vande Woude GF
    Cell; 1986 Aug; 46(5):785-94. PubMed ID: 2874888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mos gene transforming efficiencies correlate with oocyte maturation and cytostatic factor activities.
    Yew N; Oskarsson M; Daar I; Blair DG; Vande Woude GF
    Mol Cell Biol; 1991 Feb; 11(2):604-10. PubMed ID: 1703629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic activation of murine mos protein kinase by DNA rearrangement of its N-terminal coding region.
    Ohuchi T; Kurita Y; Sasai H; Miyoshi J; Nomura T; Toyoshima K
    Oncogene; 1992 Feb; 7(2):331-8. PubMed ID: 1532243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chicken homolog of the mos proto-oncogene.
    Schmidt M; Oskarsson MK; Dunn JK; Blair DG; Hughes S; Propst F; Vande Woude GF
    Mol Cell Biol; 1988 Feb; 8(2):923-9. PubMed ID: 2832744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a negative regulatory element that inhibits c-mos transcription in somatic cells.
    Zinkel SS; Pal SK; Szeberényi J; Cooper GM
    Mol Cell Biol; 1992 May; 12(5):2029-36. PubMed ID: 1533271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between physiological and transforming activities of the c-mos proto-oncogene product and identification of an essential Mos domain for these activities.
    Okazaki K; Furuno N; Watanabe N; Ikawa Y; Vande Woude GF; Sagata N
    Jpn J Cancer Res; 1991 Mar; 82(3):250-3. PubMed ID: 1827090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequences upstream from the mouse c-mos oncogene may function as a transcription termination signal.
    McGeady ML; Wood TG; Maizel JV; Vande Woude GF
    DNA; 1986 Aug; 5(4):289-98. PubMed ID: 3017657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xenopus homolog of the mos protooncogene transforms mammalian fibroblasts and induces maturation of Xenopus oocytes.
    Freeman RS; Pickham KM; Kanki JP; Lee BA; Pena SV; Donoghue DJ
    Proc Natl Acad Sci U S A; 1989 Aug; 86(15):5805-9. PubMed ID: 2527365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse c-mos oncogene activation is prevented by upstream sequences.
    Wood TG; McGeady ML; Baroudy BM; Blair DG; Vande Woude GF
    Proc Natl Acad Sci U S A; 1984 Dec; 81(24):7817-21. PubMed ID: 6096859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of non-ras transforming genes in chemical carcinogenesis.
    Cooper CS
    Environ Health Perspect; 1991 Jun; 93():33-40. PubMed ID: 1685444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long terminal repeat enhancement of v-mos transforming activity: identification of essential regions.
    Wood TG; McGeady ML; Blair DG; Vande Woude GF
    J Virol; 1983 Jun; 46(3):726-36. PubMed ID: 6190012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential.
    Katzav S; Cleveland JL; Heslop HE; Pulido D
    Mol Cell Biol; 1991 Apr; 11(4):1912-20. PubMed ID: 2005887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular cloning and characterization of the human dbl proto-oncogene: evidence that its overexpression is sufficient to transform NIH/3T3 cells.
    Ron D; Tronick SR; Aaronson SA; Eva A
    EMBO J; 1988 Aug; 7(8):2465-73. PubMed ID: 3056717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the transforming potential of the human fos proto-oncogene requires message stabilization and results in increased amounts of partially modified fos protein.
    Lee WM; Lin C; Curran T
    Mol Cell Biol; 1988 Dec; 8(12):5521-7. PubMed ID: 3149716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different promoter elements are required for the induced expression of c-fos and c-jun proto-oncogenes by the v-mos oncogene product.
    Schönthal A; Feramisco JR
    New Biol; 1990 Feb; 2(2):143-50. PubMed ID: 2150599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and expression of the murine N-myc gene.
    DePinho RA; Legouy E; Feldman LB; Kohl NE; Yancopoulos GD; Alt FW
    Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1827-31. PubMed ID: 3513190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming activity of the RL-akt gene, a c-akt gene activated by long terminal repeat insertion in murine leukemia RL(male symbol)1 cells.
    Tanino M; Matsuo M; Uenaka A; Tsukuda K; Ouchida M; Nakayama E; Shimizu K
    Mol Carcinog; 1999 Dec; 26(4):286-97. PubMed ID: 10569805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel human oncogene lbc detected by transfection with distinct homology regions to signal transduction products.
    Toksoz D; Williams DA
    Oncogene; 1994 Feb; 9(2):621-8. PubMed ID: 8290273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquisition of transforming properties by FYN, a normal SRC-related human gene.
    Kawakami T; Kawakami Y; Aaronson SA; Robbins KC
    Proc Natl Acad Sci U S A; 1988 Jun; 85(11):3870-4. PubMed ID: 3287380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.